The Experts below are selected from a list of 78726 Experts worldwide ranked by ideXlab platform
Carlo Barone - One of the best experts on this subject based on the ideXlab platform.
-
analysis of plasma protein biomarkers from the Correct Phase iii study of regorafenib for metastatic colorectal cancer
Journal of Clinical Oncology, 2013Co-Authors: Heinzjosef Lenz, Eric Van Cutsem, A Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouche, Laurent Mineur, Carlo BaroneAbstract:3514 Background: In the Correct Phase III trial, the multikinase inhibitor regorafenib (REG) demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) vs pla...
-
time profile of adverse events aes from regorafenib reg treatment for metastatic colorectal cancer mcrc in the Phase iii Correct study
Journal of Clinical Oncology, 2013Co-Authors: Axel Grothey, A Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouche, Laurent Mineur, Carlo Barone, Antoine AdenisAbstract:3637 Background: In the Correct Phase III trial, the multikinase inhibitor REG demonstrated significant improvement in overall survival and progression-free survival vs placebo (P) in patients with...
-
regorafenib reg in progressive metastatic colorectal cancer mcrc analysis of age subgroups in the Phase iii Correct trial
Journal of Clinical Oncology, 2013Co-Authors: Eric Van Cutsem, A Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouche, Laurent Mineur, Carlo Barone, Antoine AdenisAbstract:3636 Background: In the Correct Phase III trial, the multikinase inhibitor REG demonstrated significant improvement in overall survival (OS) and progression-free survival vs placebo (Pla) in patien...
Antoine Adenis - One of the best experts on this subject based on the ideXlab platform.
-
radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib post hoc analysis of the Correct Phase iii trial radioCorrect study
European Society for Medical Oncology, 2016Co-Authors: Riccardo Ricotta, Eric Van Cutsem, Alfredo Falcone, Axel Grothey, Antoine Adenis, Antonella Verrioli, Silvia Ghezzi, Luca Porcu, Guillem Argiles, Marc YchouAbstract:Objective To identify imaging markers predicting clinical outcomes to regorafenib in metastatic colorectal carcinoma (mCRC). Methods The RadioCorrect study is a post hoc analysis of a cohort of patients with mCRC treated within the Phase III placebo-controlled Correct trial of regorafenib. Baseline and week 8 contrast-enhanced CT were used to assess response by RECIST 1.1, changes in the sum of target lesion diameters (ΔSTL), lung metastases cavitation and liver metastases density. Primary and secondary objectives were to develop ex novo univariable and multivariable models to predict overall survival (OS) and progression-free survival (PFS), respectively. Results 202 patients were enrolled, 134 (66.3%) treated with regorafenib and 68 (33.7%) with placebo. In the univariate analysis, PFS predictors were lung metastases cavitation at baseline (HR 0.50, 95% CI 0.27 to 0.92, p=0.03) and at week 8 (HR 0.58, 95% CI 0.36 to 0.93, p=0.02). Baseline cavitation (HR 0.23, 95% CI 0.08 to 0.66, p=0.007), RECIST 1.1 (HR 0.23, 95% CI 0.14 to 0.4, p Conclusions RECIST 1.1 and ΔSTL predict favourable outcome to regorafenib. In contrast to liver metastases density that failed to be a predictor, lung metastases cavitation represents a novel radiological marker of favourable outcome that deserves consideration.
-
time profile of adverse events aes from regorafenib reg treatment for metastatic colorectal cancer mcrc in the Phase iii Correct study
Journal of Clinical Oncology, 2013Co-Authors: Axel Grothey, A Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouche, Laurent Mineur, Carlo Barone, Antoine AdenisAbstract:3637 Background: In the Correct Phase III trial, the multikinase inhibitor REG demonstrated significant improvement in overall survival and progression-free survival vs placebo (P) in patients with...
-
regorafenib reg in progressive metastatic colorectal cancer mcrc analysis of age subgroups in the Phase iii Correct trial
Journal of Clinical Oncology, 2013Co-Authors: Eric Van Cutsem, A Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouche, Laurent Mineur, Carlo Barone, Antoine AdenisAbstract:3636 Background: In the Correct Phase III trial, the multikinase inhibitor REG demonstrated significant improvement in overall survival (OS) and progression-free survival vs placebo (Pla) in patien...
Duane D Johnson - One of the best experts on this subject based on the ideXlab platform.
-
topologically Correct Phase boundaries and transition temperatures for ising hamiltonians via self consistent coarse grained cluster lattice models
Physical Review B, 2011Co-Authors: Teck L Tan, Duane D JohnsonAbstract:We derive a cluster mean-field theory for an Ising Hamiltonian using a cluster-lattice Fourier transform with a cluster of size ${N}_{\mathrm{c}}$ and a coarse-grained (CG) lattice into cells of size ${N}_{\mathrm{cell}}$. We explore forms with ${N}_{\mathrm{cell}}\ensuremath{\geqslant}{N}_{\mathrm{c}}$, including a non-CG (NCG) version with ${N}_{\mathrm{cell}}\ensuremath{\rightarrow}\ensuremath{\infty}$. For ${N}_{\text{c}}={N}_{\mathrm{cell}}$, the set of static, self-consistent equations relating cluster and CG lattice correlations is analogous to that in dynamical cluster approximation and cellular dynamical mean-field theory used in correlated electron physics. A variational ${N}_{\mathrm{c}}$-site cluster grand potential based on ${N}_{\mathrm{c}}={N}_{\mathrm{cell}}$ CG lattice maintains thermodynamic consistency and improves predictions, recovering Monte Carlo and series expansion results upon finite-size scaling; notably, the ${N}_{\mathrm{c}}=1$ CG results already predict well the first- and second-order Phase boundary topology and transition temperatures for frustrated lattices. The NCG version is significantly faster computationally than the CG case and more accurate at fixed ${N}_{\mathrm{c}}$ for ferromagnetism, which is potentially useful for cluster expansion and quantum cluster applications.
Eric Van Cutsem - One of the best experts on this subject based on the ideXlab platform.
-
radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib post hoc analysis of the Correct Phase iii trial radioCorrect study
European Society for Medical Oncology, 2016Co-Authors: Riccardo Ricotta, Eric Van Cutsem, Alfredo Falcone, Axel Grothey, Antoine Adenis, Antonella Verrioli, Silvia Ghezzi, Luca Porcu, Guillem Argiles, Marc YchouAbstract:Objective To identify imaging markers predicting clinical outcomes to regorafenib in metastatic colorectal carcinoma (mCRC). Methods The RadioCorrect study is a post hoc analysis of a cohort of patients with mCRC treated within the Phase III placebo-controlled Correct trial of regorafenib. Baseline and week 8 contrast-enhanced CT were used to assess response by RECIST 1.1, changes in the sum of target lesion diameters (ΔSTL), lung metastases cavitation and liver metastases density. Primary and secondary objectives were to develop ex novo univariable and multivariable models to predict overall survival (OS) and progression-free survival (PFS), respectively. Results 202 patients were enrolled, 134 (66.3%) treated with regorafenib and 68 (33.7%) with placebo. In the univariate analysis, PFS predictors were lung metastases cavitation at baseline (HR 0.50, 95% CI 0.27 to 0.92, p=0.03) and at week 8 (HR 0.58, 95% CI 0.36 to 0.93, p=0.02). Baseline cavitation (HR 0.23, 95% CI 0.08 to 0.66, p=0.007), RECIST 1.1 (HR 0.23, 95% CI 0.14 to 0.4, p Conclusions RECIST 1.1 and ΔSTL predict favourable outcome to regorafenib. In contrast to liver metastases density that failed to be a predictor, lung metastases cavitation represents a novel radiological marker of favourable outcome that deserves consideration.
-
subgroup analysis of patients enrolled in the united states in the Correct Phase 3 trial of the multikinase inhibitor regorafenib reg in metastatic colorectal cancer mcrc
Journal of Clinical Oncology, 2015Co-Authors: George P Kim, Heinzjosef Lenz, Eric Van Cutsem, Udit Verma, Marc Saltzman, Jyotsna Fuloria, Ali Khojasteh, Martin Wiesenfeld, Frank Cihon, Andrea WagnerAbstract:767 Background: The Correct trial (NCT01103323) showed that REG improves overall survival (OS) vs placebo (PBO) in patients with mCRC who failed approved therapies (OS HR 0.77; 1-sided p=0.0052; Gr...
-
analysis of plasma protein biomarkers from the Correct Phase iii study of regorafenib for metastatic colorectal cancer
Journal of Clinical Oncology, 2013Co-Authors: Heinzjosef Lenz, Eric Van Cutsem, A Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouche, Laurent Mineur, Carlo BaroneAbstract:3514 Background: In the Correct Phase III trial, the multikinase inhibitor regorafenib (REG) demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) vs pla...
-
regorafenib reg in progressive metastatic colorectal cancer mcrc analysis of age subgroups in the Phase iii Correct trial
Journal of Clinical Oncology, 2013Co-Authors: Eric Van Cutsem, A Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouche, Laurent Mineur, Carlo Barone, Antoine AdenisAbstract:3636 Background: In the Correct Phase III trial, the multikinase inhibitor REG demonstrated significant improvement in overall survival (OS) and progression-free survival vs placebo (Pla) in patien...
J N Turner - One of the best experts on this subject based on the ideXlab platform.
-
electron diffraction from phospholipids an approximate Correction for dynamical scattering and tests for a Correct Phase determination
Journal of Applied Crystallography, 1993Co-Authors: Douglas L Dorset, William F. Tivol, M. P. Mccourt, J N TurnerAbstract:An approximate experimental Correction of electron diffraction intensities from an epitaxically crystallized phospholipid bilayer for dynamical scattering is described. This Correction, which is useful for certain low-angle centrosymmetric data sets, compares intensities recorded at high and low electron-accelerating voltages to ascertain which reflections are most affected by n-beam interactions. When applied to experimental intensity data from 1,2-dihexadecyl-sn-glycerophosphoethanolamine (DHPE), the Correction facilitates a direct Phase determination based on the probabilistic estimate of three-Phase invariants because a more accurate estimate of the hierarchy of |El| values is obtained. When a multisolution technique is used, incorporating algebraic unknowns for certain Phase values, the best Phase assignment can be assessed by comparison of the single convolution of Phased structure factors to the observed structure-factor magnitudes for the low-voltage data. This approach exploits an approximate analogy made earlier by Moodie between the Sayre equation and the Phase grating series and is valid as long as the single convolution adequately models experimental low-voltage data (a condition favored by light-atom structures in a low-angle region of reciprocal space). In real space, the Correct structure can also be readily identified as the one having the smoothest density profile.
-
electron diffraction from phospholipids an approximate Correction for dynamical scattering and tests for a Correct Phase determination
Journal of Applied Crystallography, 1993Co-Authors: Douglas L Dorset, William F. Tivol, M. P. Mccourt, J N TurnerAbstract:An approximate experimental Correction of electron diffraction intensities from an epitaxically crystallized phospholipid bilayer for dynamical scattering is described. This Correction, which is useful for certain low-angle centrosymmetric data sets, compares intensities recorded at high and low electron-accelerating voltages to ascertain which reflections are most affected by n-beam interactions. When applied to experimental intensity data from 1,2-dihexadecyl-sn-glycerophosphoethanolamine (DHPE), the Correction facilitates a direct Phase determination based on the probabilistic estimate of three-Phase invariants because a more accurate estimate of the hierarchy of |El| values is obtained. When a multisolution technique is used, incorporating algebraic unknowns for certain Phase values, the best Phase assignment can be assessed by comparison of the single convolution of Phased structure factors to the observed structure-factor magnitudes for the low-voltage data. This approach exploits an approximate analogy made earlier by Moodie between the Sayre equation and the Phase grating series and is valid as long as the single convolution adequately models experimental low-voltage data (a condition favored by light-atom structures in a low-angle region of reciprocal space). In real space, the Correct structure can also be readily identified as the one having the smoothest density profile.